Maria Maddalena Laterza, Secretary at GOY (Gastro Oncology Young), shared on LinkedIn:
“Biomarkers: from testing to clinical impact.
Great insights from ESMO 2026, particularly the session on Challenges in Biomarker Testing in gastroesophageal cancer.
Key takeaways:
- Biomarker testing is essential for precision oncology.
- Tumour heterogeneity and testing standardisation remain major challenges.
- The real value of biomarkers lies in translating biological insights into clinical decisions.
These challenges strongly resonate with our EARLY research project, highlighting the importance of biomarker-driven approaches for better patient stratification and more personalised care.
The future is not just about identifying biomarkers, but making them clinically meaningful.”
Follow the latest from ESMO 2026 with OncoDaily.